Zerbini Gianpaolo, Gabellini Daniela, Maestroni Silvia, Maestroni Anna
Renal Pathophysiology Unit, Section for Nutrition-Metabolism, Department of Medicine, San Raffaele Scientific Institute, Milan - Italy.
J Nephrol. 2007 Nov-Dec;20 Suppl 12:S19-22.
Diabetic nephropathy develops in only a subgroup of patients affected by type 1 diabetes. Once established, this complication is quite difficult to control, and consequently its prevention is presently considered the first target to achieve. As hyperglycemia has immediate effects on renal function and structure, it is reasonable to say that, in predisposed individuals, the pathogenesis of diabetic nephropathy also begins with the onset of diabetes. Two major hypotheses have been put forward to explain how the renal abnormalities that characterize the first years of diabetes - i.e., hyperfiltration and hypertrophy - will later lead to the appearance of microalbuminuria and end-stage renal disease. The first hypothesis considers hyperfiltration as the driving dysfunction and hypertrophy as the consequence. Conversely, the second points to proximal tubule hypertrophy as the starting point and hyperfiltration as the result. Whatever the case, tight glucose control from the very first days of disease seems to be the only established therapy to prevent future complications in type 1 diabetes.
糖尿病肾病仅在一部分1型糖尿病患者中发生。一旦出现,这种并发症很难控制,因此目前认为预防是首要目标。由于高血糖对肾功能和结构有直接影响,可以合理地说,在易感个体中,糖尿病肾病的发病机制也始于糖尿病的发病。已经提出了两种主要假说来解释糖尿病最初几年的特征性肾脏异常——即高滤过和肥大——随后如何导致微量白蛋白尿和终末期肾病的出现。第一种假说认为高滤过是驱动性功能障碍,肥大是结果。相反,第二种假说指出近端肾小管肥大是起点,高滤过是结果。无论哪种情况,从疾病最初几天就严格控制血糖似乎是预防1型糖尿病未来并发症的唯一既定疗法。